Aliases & Classifications for Vaccinia

MalaCards integrated aliases for Vaccinia:

Name: Vaccinia 12 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3298
MeSH 44 D014615
UMLS 73 C0042214

Summaries for Vaccinia

Disease Ontology : 12 A viral infectious disease that results in infection, located in skin, has material basis in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted by contact with the vaccination site before it has healed, or transmitted by fomites that have been contaminated with live virus from the vaccination site. The infection has symptom rash, has symptom fever, and has symptom body aches.

MalaCards based summary : Vaccinia is related to viral infectious disease and cowpox, and has symptoms including fever, rash and body aches. An important gene associated with Vaccinia is VRK1 (VRK Serine/Threonine Kinase 1), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Immunologic Factors and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include prostate, t cells and skin, and related phenotypes are hematopoietic system and immune system

Wikipedia : 76 Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It... more...

Related Diseases for Vaccinia

Graphical network of the top 20 diseases related to Vaccinia:



Diseases related to Vaccinia

Symptoms & Phenotypes for Vaccinia

Symptoms:

12
  • fever
  • rash
  • body aches

MGI Mouse Phenotypes related to Vaccinia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 AZI2 BTRC DUSP3 EIF2AK2 EPS15 IL2
2 immune system MP:0005387 9.32 AZI2 BTRC EIF2AK2 EPS15 IL2 IRF3

Drugs & Therapeutics for Vaccinia

Drugs for Vaccinia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
3 Immunoglobulins, Intravenous Phase 4,Phase 2,Phase 1
4 gamma-Globulins Phase 4,Phase 2,Phase 1
5 Antibodies Phase 4,Phase 2,Phase 1
6 Immunoglobulins Phase 4,Phase 2,Phase 1
7 Rho(D) Immune Globulin Phase 4,Phase 2,Phase 1
8
Nicotinamide Approved, Investigational Phase 3,Phase 2 98-92-0 936
9
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
10
Carboplatin Approved Phase 2, Phase 3,Not Applicable 41575-94-4 10339178 38904 498142
11
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 33069-62-4 36314
12
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
13
Cisplatin Approved Phase 2, Phase 3,Phase 1 15663-27-1 2767 441203 84093
14
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
15
Pemetrexed Approved, Investigational Phase 2, Phase 3 150399-23-8, 137281-23-3 446556 60843
16
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
18
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
19 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
20 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
21 Analgesics Phase 3,Phase 2,Phase 1
22 Anticonvulsants Phase 3
23 Neurotropin Phase 3
24 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
25 Krestin Phase 3,Phase 2,Phase 1
26 Iron-Dextran Complex Phase 3,Phase 2
27 Vitamin B Complex Phase 3,Phase 2
28 Vitamin B9 Phase 3,Phase 2
29 Protein Kinase Inhibitors Phase 3,Phase 2
30 Vitamins Phase 3,Phase 2
31 Vitamin B3 Phase 3,Phase 2
32 Folate Phase 3,Phase 2
33 Nicotinic Acids Phase 3,Phase 2
34 Trace Elements Phase 3,Phase 2
35 Micronutrients Phase 3,Phase 2
36 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
37 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
38 Antiviral Agents Phase 2, Phase 3,Phase 1
39 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
40 Antimitotic Agents Phase 2, Phase 3,Phase 1
41 Antimetabolites Phase 2, Phase 3,Phase 1
42 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 1,Not Applicable
43 Angiogenesis Inhibitors Phase 3,Phase 2
44 Angiogenesis Modulating Agents Phase 2, Phase 3
45 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
46
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
47 Folic Acid Antagonists Phase 2, Phase 3
48
Metronidazole Approved Phase 2,Phase 1,Not Applicable 443-48-1 4173
49
Goserelin Approved Phase 2 65807-02-5 47725 5311128
50
Bicalutamide Approved Phase 2 90357-06-5 2375 56069

Interventional clinical trials:

(show top 50) (show all 259)
# Name Status NCT ID Phase Drugs
1 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous(VIGIV) Completed NCT01158157 Phase 4
2 Special Access Program IMVAMUNE® Completed NCT03472014 Phase 4
3 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
4 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Recruiting NCT02443623 Phase 4
5 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT01144637 Phase 3
6 Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
7 Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
8 Analgecine for the Treatment of Neuropathic Pain Completed NCT02633618 Phase 3
9 A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543567 Phase 3
10 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543268 Phase 3
11 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Recruiting NCT02562755 Phase 3 Sorafenib
12 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
13 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
14 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Active, not recruiting NCT01913353 Phase 3
15 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Active, not recruiting NCT02509494 Phase 3
16 Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial Not yet recruiting NCT03699124 Phase 3
17 Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Terminated NCT01383148 Phase 2, Phase 3 placebo
18 Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002817 Phase 1, Phase 2
19 Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Unknown status NCT00103584 Phase 1, Phase 2
20 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
21 A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis Completed NCT01443260 Phase 1, Phase 2
22 Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma Completed NCT00116597 Phase 1, Phase 2
23 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT00554372 Phase 2
24 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
25 Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) Completed NCT01705223 Phase 2
26 A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma Completed NCT00429312 Phase 1, Phase 2
27 High Dose IMVAMUNE® in Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
28 PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer Completed NCT00088413 Phase 2 Sargramostim (GM-CSF, Leukine)
29 A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
30 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Completed NCT00108732 Phase 2 Bicalutamide;Goserelin Acetate
31 Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma Completed NCT01394939 Phase 1, Phase 2 Irinotecan
32 APSV in Vaccinia Naive Adults Completed NCT00050518 Phase 2
33 A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib Completed NCT01387555 Phase 2
34 Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Completed NCT00038987 Phase 1, Phase 2
35 A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer Completed NCT01636284 Phase 2
36 A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT01171651 Phase 2 JX-594 followed by sorafenib
37 Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer Completed NCT00179309 Phase 2 Docetaxel
38 Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally Completed NCT00914732 Phase 2
39 Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Completed NCT02919306 Phase 1, Phase 2 Placebo
40 ACAM 3000 MVA at Harvard Medical School Completed NCT00133575 Phase 1, Phase 2
41 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00019734 Phase 2
42 Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00054535 Phase 2
43 Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Completed NCT00112957 Phase 2
44 Dressing Preparations for Smallpox Completed NCT00063856 Phase 1, Phase 2
45 A Study of MVA85A in Healthy Children and Infants Completed NCT00679159 Phase 2
46 Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors Completed NCT00003125 Phase 2
47 Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults Completed NCT00820846 Phase 2
48 MVA Post-Event: Administration Timing and Boost Study Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
49 Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines Completed NCT01461447 Phase 1, Phase 2
50 Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Completed NCT00052351 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel

Search NIH Clinical Center for Vaccinia

Cochrane evidence based reviews: vaccinia

Genetic Tests for Vaccinia

Anatomical Context for Vaccinia

MalaCards organs/tissues related to Vaccinia:

41
Prostate, T Cells, Skin, Liver, Lung, Colon, Nk Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Vaccinia:

19
Skin

Publications for Vaccinia

Articles related to Vaccinia:

(show top 50) (show all 1565)
# Title Authors Year
1
Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer. ( 30365143 )
2019
2
Oncolytic cancer therapy with a vaccinia virus strain. ( 30365140 )
2019
3
<i>Tachypleus tridentatus</i> Lectin Enhances Oncolytic Vaccinia Virus Replication to Suppress In Vivo Hepatocellular Carcinoma Growth. ( 29880736 )
2018
4
Ocular Vaccinia Infection in Dairy Worker, Brazil. ( 29260673 )
2018
5
First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. ( 29669026 )
2018
6
Vaccinia virus in Feces and Urine of Wild Rodents from SALo Paulo State, Brazil. ( 29360742 )
2018
7
Antigenicity of <i>Leishmania</i>-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters. ( 29740446 )
2018
8
Vaccinia virus C9 ankyrin-repeat/F-box protein is a newly identified antagonist of the type I interferon-induced antiviral state. ( 29444943 )
2018
9
Genital Autoinoculation with Vaccinia: A Look at Two Cases. ( 29415160 )
2018
10
Vaccinia-based vaccines to biothreat and emerging viruses. ( 29779454 )
2018
11
Inhibition of vaccinia virus replication by nitazoxanide. ( 29625403 )
2018
12
High Initial Sputter Rate Found for Vaccinia Virions Using Isotopic Labeling, NanoSIMS, and AFM. ( 29295620 )
2018
13
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. ( 29259007 )
2018
14
E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox. ( 29300297 )
2018
15
Vaccinia Virus Protein C6: A Multifunctional Interferon Antagonist. ( 29785476 )
2018
16
In vitro susceptibility to ST-246 and Cidofovir corroborates the phylogenetic separation of Brazilian Vaccinia virus into two clades. ( 29427676 )
2018
17
Vaccinia Virus in Blood Samples of Humans, Domestic and Wild Mammals in Brazil. ( 29346277 )
2018
18
A Novel System for Constructing a Recombinant Highly-Attenuated Vaccinia Virus Strain (LC16m8) Expressing Foreign Genes and Its Application for the Generation of LC16m8-Based Vaccines against Herpes Simplex Virus 2. ( 29709968 )
2018
19
DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination. ( 29869530 )
2018
20
Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase. ( 29599502 )
2018
21
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines. ( 29692427 )
2018
22
Septins suppress the release of vaccinia virus from infected cells. ( 29921601 )
2018
23
Lamin A/C augments Th1 differentiation and response against vaccinia virus and Leishmania major. ( 29311549 )
2018
24
The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host. ( 29678552 )
2018
25
Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-I94 with a Set of Gene Deletions on Several Viral Pathways. ( 29367944 )
2018
26
Weak vaccinia virus-induced NK cell regulation of CD4 T cells is associated with reduced NK cell differentiation and cytolytic activity. ( 29715623 )
2018
27
Mechanism of vaccinia viral protein B14-mediated inhibition of II_B kinase I^ activation. ( 29748387 )
2018
28
Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine. ( 29922280 )
2018
29
Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis. ( 29773661 )
2018
30
<i>Haliotis discus discus</i> Sialic Acid-Binding Lectin Reduces the Oncolytic Vaccinia Virus Induced Toxicity in a Glioblastoma Mouse Model. ( 29701680 )
2018
31
Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against <i>Mycobacterium tuberculosis</i>. ( 29847865 )
2018
32
Mutagenic repair of double-stranded DNA breaks in vaccinia virus genomes requires cellular DNA ligase IV activity in the cytosol. ( 29676720 )
2018
33
A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge. ( 29339750 )
2018
34
A comparison of the effect of molluscum contagiosum virus MC159 and MC160 proteins on vaccinia virus virulence in intranasal and intradermal infection routes. ( 29393023 )
2018
35
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. ( 29399394 )
2018
36
Discovery of a new class of inhibitors of Vaccinia virus based on (-)-borneol from A8bies sibA-rica and (+)-camphor. ( 29956885 )
2018
37
Labeling and Single-Particle-Tracking-Based Entry Mechanism Study of Vaccinia Virus from the Tiantan Strain. ( 29392930 )
2018
38
Immunisation of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins. ( 29386289 )
2018
39
A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses. ( 29581442 )
2018
40
Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression. ( 30096846 )
2018
41
Antiviral activity of metal chelates of caffeic acid and similar compounds towards herpes simplex, VSV-Ebola pseudotyped and vaccinia viruses. ( 30393014 )
2018
42
Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus. ( 30410347 )
2018
43
Construction and characterization of bacterial artificial chromosomes harboring the full-length genome of a highly attenuated vaccinia virus LC16m8. ( 29474493 )
2018
44
Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory. ( 29495547 )
2018
45
The Host Restriction Factor Interferon-Inducible Transmembrane Protein 3 Inhibits Vaccinia Virus Infection. ( 29503647 )
2018
46
Bovine Vaccinia: Insights into the Disease in Cattle. ( 29522489 )
2018
47
Characterization of the immune response elicited by the vaccinia virus L3 protein delivered as naked DNA. ( 29525282 )
2018
48
The use of the vaccinia virus complement control protein (VCP) in the rat retina. ( 29534078 )
2018
49
Vaccinia Virus Phospholipase Protein F13 Promotes Rapid Entry of Extracellular Virions into Cells. ( 29540596 )
2018
50
Full Genome Sequence of the Western Reserve Strain of Vaccinia Virus Determined by Third-Generation Sequencing. ( 29545308 )
2018

Variations for Vaccinia

Expression for Vaccinia

Search GEO for disease gene expression data for Vaccinia.

Pathways for Vaccinia

Pathways related to Vaccinia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 BTRC CUL1 DUSP3 EIF2AK2 IL2 IRF3
2
Show member pathways
12.71 IL2 IRF3 IRF7 NLRP1 TANK
3
Show member pathways
12.45 CUL1 EIF2AK2 IL2 IRF3 IRF7
4
Show member pathways
12.39 AZI2 IRF3 IRF7 TANK TBKBP1
5
Show member pathways
11.87 BTRC CUL1 IRF7 TANK
6 11.73 EIF2AK2 IRF3 IRF7
7 11.61 IL2 IRF3 IRF7 NLRP1 TANK TBKBP1
8
Show member pathways
10.85 BANF1 VRK1 VRK2
9
Show member pathways
10.49 EIF2AK2 IRF3 IRF7

GO Terms for Vaccinia

Cellular components related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.47 BANF1 BTRC CUL1 DUSP3 EIF2AK2 EPS15

Biological processes related to Vaccinia according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.92 EIF2AK2 IL2 IRF3 IRF7 NLRP1
2 innate immune response GO:0045087 9.88 EIF2AK2 IRF3 IRF7 NLRP1 TBKBP1
3 membrane organization GO:0061024 9.74 EPS15 ITSN1 WASL
4 response to virus GO:0009615 9.71 BANF1 EIF2AK2 IRF7
5 peptidyl-threonine phosphorylation GO:0018107 9.58 VRK1 VRK2 VRK3
6 NIK/NF-kappaB signaling GO:0038061 9.56 BTRC CUL1
7 positive regulation of kinase activity GO:0033674 9.55 IL2 ITSN1
8 vesicle organization GO:0016050 9.51 EPS15 WASL
9 positive regulation of interferon-alpha production GO:0032727 9.49 IRF3 IRF7
10 regulation of type I interferon production GO:0032479 9.46 IRF3 IRF7
11 viral process GO:0016032 9.44 AZI2 BANF1 BTRC CUL1 EIF2AK2 EPS15
12 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.43 IRF3 IRF7
13 mitotic nuclear envelope reassembly GO:0007084 9.37 BANF1 VRK1
14 MDA-5 signaling pathway GO:0039530 9.32 IRF3 IRF7
15 type I interferon biosynthetic process GO:0045351 9.26 IRF3 IRF7
16 interferon-alpha production GO:0032607 9.16 AZI2 IRF7
17 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.13 IRF3 IRF7 TANK

Molecular functions related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 AZI2 BANF1 BTRC CUL1 EIF2AK2 EPS15
2 kinase activator activity GO:0019209 8.96 IL2 ITSN1

Sources for Vaccinia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....